Sean M. Smith

4.3k total citations · 1 hit paper
57 papers, 2.8k citations indexed

About

Sean M. Smith is a scholar working on Molecular Biology, Physiology and Organic Chemistry. According to data from OpenAlex, Sean M. Smith has authored 57 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 15 papers in Physiology and 13 papers in Organic Chemistry. Recurrent topics in Sean M. Smith's work include Phosphodiesterase function and regulation (16 papers), Cholinesterase and Neurodegenerative Diseases (10 papers) and Receptor Mechanisms and Signaling (10 papers). Sean M. Smith is often cited by papers focused on Phosphodiesterase function and regulation (16 papers), Cholinesterase and Neurodegenerative Diseases (10 papers) and Receptor Mechanisms and Signaling (10 papers). Sean M. Smith collaborates with scholars based in United States, Germany and United Kingdom. Sean M. Smith's co-authors include Wylie Vale, James M. Takacs, Jason M. Uslaner, Nathan C. Thacker, Joan Vaughan, Peter H. Hutson, Alon Chen, Chien Li, Lihang Yao and Dawn Toolan and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Sean M. Smith

55 papers receiving 2.8k citations

Hit Papers

The role of the hypothalamic-pituitary-adrenal axis in ne... 2006 2026 2012 2019 2006 400 800 1.2k

Peers

Sean M. Smith
Geoffrey B. Varty United States
Durk Fekkes Netherlands
John A. Moyer United States
Carlo Contoreggi United States
Geoffrey B. Varty United States
Sean M. Smith
Citations per year, relative to Sean M. Smith Sean M. Smith (= 1×) peers Geoffrey B. Varty

Countries citing papers authored by Sean M. Smith

Since Specialization
Citations

This map shows the geographic impact of Sean M. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sean M. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sean M. Smith more than expected).

Fields of papers citing papers by Sean M. Smith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sean M. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sean M. Smith. The network helps show where Sean M. Smith may publish in the future.

Co-authorship network of co-authors of Sean M. Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Sean M. Smith. A scholar is included among the top collaborators of Sean M. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sean M. Smith. Sean M. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Mukai, Yuki, Robert Lupinacci, Stephen R. Marder, et al.. (2024). Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial. Schizophrenia Research. 270. 37–43. 10 indexed citations
3.
Smith, Sean M., Dawn Toolan, Monika Kandebo, et al.. (2024). Preclinical evaluation of MK-8189: A novel phosphodiesterase 10A inhibitor for the treatment of schizophrenia. Journal of Pharmacology and Experimental Therapeutics. 392(1). 100047–100047. 1 indexed citations
4.
Layton, M. E., Jeffrey C. Kern, William D. Shipe, et al.. (2023). Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia. Journal of Medicinal Chemistry. 66(2). 1157–1171. 22 indexed citations
5.
Kandebo, Monika, Lihang Yao, Bang-Lin Wan, et al.. (2022). Neuronopathic GBA1L444P Mutation Accelerates Glucosylsphingosine Levels and Formation of Hippocampal Alpha-Synuclein Inclusions. Journal of Neuroscience. 43(3). 501–521. 22 indexed citations
6.
Zhang, Nanyan, Nathan G. Hatcher, Kim Ekroos, et al.. (2022). Validation of a multiplexed and targeted lipidomics assay for accurate quantification of lipidomes. Journal of Lipid Research. 63(6). 100218–100218. 16 indexed citations
7.
Jinn, Sarah, Lihang Yao, Monika Kandebo, et al.. (2021). A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy. Neurobiology of Disease. 159. 105507–105507. 14 indexed citations
8.
Rocha, Emily M., Briana R. De Miranda, Sandra L. Castro, et al.. (2019). LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease. Neurobiology of Disease. 134. 104626–104626. 61 indexed citations
9.
Stachel, Shawn J., Melissa S. Egbertson, Jenny Wai, et al.. (2018). Indole acids as a novel PDE2 inhibitor chemotype that demonstrate pro-cognitive activity in multiple species. Bioorganic & Medicinal Chemistry Letters. 28(6). 1122–1126. 3 indexed citations
10.
Stachel, Shawn J., Richard Berger, Daniel V. Paone, et al.. (2018). Structure-Guided Design and Procognitive Assessment of a Potent and Selective Phosphodiesterase 2A Inhibitor. ACS Medicinal Chemistry Letters. 9(8). 815–820. 13 indexed citations
11.
Vardigan, Joshua D., Henry S. Lange, Spencer J. Tye, et al.. (2016). Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity. Psychopharmacology. 233(13). 2441–2450. 3 indexed citations
12.
Ramirez, Andres D. & Sean M. Smith. (2015). Regulation of Dopamine Signaling in the Striatum by Phosphodiesterase Inhibitors: Novel Therapeutics to Treat Neurological and Psychiatric Disorders. Central Nervous System Agents in Medicinal Chemistry. 14(2). 72–82. 23 indexed citations
13.
Smith, Sean M., et al.. (2012). γ-Selective directed catalytic asymmetric hydroboration of 1,1-disubstituted alkenes. Chemical Communications. 48(100). 12180–12180. 41 indexed citations
14.
Smith, Sean M., Jason M. Uslaner, Christopher D. Cox, et al.. (2012). The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology. 64. 215–223. 70 indexed citations
15.
Smith, Sean M., et al.. (2011). Catalytic asymmetric hydroboration of β,γ-unsaturated Weinreb amides: striking influence of the borane. Chemical Communications. 47(27). 7812–7812. 24 indexed citations
17.
Smith, Sean M., Jason M. Uslaner, Lihang Yao, et al.. (2008). The Behavioral and Neurochemical Effects of a Novel d-Amino Acid Oxidase Inhibitor Compound 8 [4 H-Thieno [3,2-b]pyrrole-5-carboxylic Acid] and d-Serine. Journal of Pharmacology and Experimental Therapeutics. 328(3). 921–930. 73 indexed citations
18.
Chen, Alon, Eric P. Zorrilla, Sean M. Smith, et al.. (2006). Urocortin 2-Deficient Mice Exhibit Gender-Specific Alterations in Circadian Hypothalamus–Pituitary–Adrenal Axis and Depressive-Like Behavior. Journal of Neuroscience. 26(20). 5500–5510. 77 indexed citations
19.
Smith, Sean M., Joan Vaughan, Cynthia J. Donaldson, et al.. (2005). Cocaine- and Amphetamine-Regulated Transcript Is Localized in Pituitary Lactotropes and Is Regulated during Lactation. Endocrinology. 147(3). 1213–1223. 20 indexed citations
20.
Smith, Sean M., Joan Vaughan, Cynthia J. Donaldson, et al.. (2004). Cocaine- and Amphetamine-Regulated Transcript Activates the Hypothalamic-Pituitary-Adrenal Axis through a Corticotropin-Releasing Factor Receptor-Dependent Mechanism. Endocrinology. 145(11). 5202–5209. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026